Skip to content
The Policy VaultThe Policy Vault

Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir)Blue Cross Blue Shield of Kansas

Chronic hepatitis C (various genotypes)

Preferred products

  • Epclusa (sofosbuvir/velpatasvir)
  • Harvoni (ledipasvir/sofosbuvir)
  • Ledipasvir/Sofosbuvir
  • Mavyret (glecaprevir/pibrentasvir)
  • Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
  • Zepatier (elbasvir/grazoprevir)

Initial criteria

  • Target Agent will be approved when ALL of the following are met:
  • Must meet the same baseline criteria as Sovaldi policy criteria (appropriate genotype, prior therapy, specialist involvement, HBV screening, no contraindications, etc.).

Approval duration

up to duration of treatment per FDA labeling